---
figid: PMC9266842__ijms-23-07353-g001
pmcid: PMC9266842
image_filename: ijms-23-07353-g001.jpg
figure_link: /pmc/articles/PMC9266842/figure/ijms-23-07353-f001/
number: Figure 1
figure_title: ''
caption: Percentage of TNBC, non-TNBC, and melanoma patients with mutations in the
  PI3K and MAPK pathways. Mutations in each pathway were identified as somatic genetic
  variant in at least one gene from the PI3K pathway (PTEN, PIK3CA, AKT1, ERBB2, PIK3R1)
  or RAS pathway (HRAS, KRAS, NRAS, BRAF, NF1, and SOS1). TNBC, triple-negative breast
  cancer.
article_title: Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition
  Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast
  Cancer.
citation: Zhizhu Zhang, et al. Int J Mol Sci. 2022 Jul;23(13):7353.
year: '2022'

doi: 10.3390/ijms23137353
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI

keywords:
- melanoma
- triple-negative breast cancer
- PI3K/AKT/mTOR
- MAPK/MEK/ERK
- immune checkpoint blockade

---
